Document is current
Any future updates will be listed below
-
Authors
Huskic, Sara
Lazen, Philipp
Cadrien, Cornelius
Roetzer-Pejrimovsky, Thomas
Kiesel, Barbara
Furtner, Julia
Leitner, Johannes
Kloss-Brandstätter, Anita
Körner, Lisa
Berghoff, Anna Sophie
Preusser, Matthias
Grabner, Günther
Bogner, Wolfgang
Traub-Weidinger, Tatjana
Hacker, Marcus
Trattnig, Siegfried
Rössler, Karl
Hangel, Gilbert
Widhalm, Georg https://orcid.org/0000-0001-6014-0273
-
Funding
Funding for this research was provided by:
Austrian Science Fund (https://doi.org/10.55776/DFH50)
Austrian Science Fund (https://doi.org/10.55776/KLI1089)
- License Information
-
More Information
Article History
Received: 15 October 2025
Revised: 24 January 2026
Accepted: 6 February 2026
First Online: 10 March 2026
Compliance with ethical standards
:
: The scientific guarantor of this publication is Georg Widhalm.
: The authors of this manuscript declare relationships with the following companies: Julia Furtner has received honoraria for lectures and consultation from the following for-profit companies: Novartis and Seagen. Matthias Preusser has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals, and Servier.
: Anita Kloss-Brandstaetter kindly provided statistical advice for this manuscript.
: Written informed consent was obtained from all subjects (patients) in this study.
: Our research has been conducted in compliance with the relevant ethical standards. Institutional Review Board (IRB) approval was obtained by the IRB of the Medical University of Vienna, protocol 1991/2018.
: This manuscript includes a patient cohort that partially overlaps with our previous publications ( n = 15 in Hangel et al [ ]; n = 17 in Hangel et al [ ]; n = 22 in Cadrien et al [ ]; n = 11 in Lazen et al [ ]), while addressing a distinct research question. Specifically, Hangel et al [ ] evaluated the feasibility of 7-T MRSI in gliomas, Hangel et al [ ] examined its relationship with PET imaging, Lazen et al [ ] investigated correlations between 7-T MRSI and MR fingerprinting, and Cadrien et al [ ] focused on glioma grading and IDH-status classification using 7-T MRSI.
:
